Revolution Medicines Dividend

Dividend criteria checks 0/6

Revolution Medicines hat in der Vergangenheit keine Dividende gezahlt.

Key information

n/a

Dividend yield

n/a

Payout ratio

Industry average yield	2.8%
Next dividend pay date	n/a
Ex dividend date	n/a
Dividend per share	n/a
Earnings per share	-US$2.65
Dividend yield forecast in 3Y	0%

Recent dividend updates

No updates

Recent updates

Revolution Medicines Is Hard To Understand

Feb 01

Here's Why We're Not Too Worried About Revolution Medicines' (NASDAQ:RVMD) Cash Burn Situation

Aug 09

New Forecasts: Here's What Analysts Think The Future Holds For Revolution Medicines, Inc. (NASDAQ:RVMD)

Aug 10

Revolution Medicines to raise up to $200M in stock offering

Jul 19

Revolution Medicines, Inc. (NASDAQ:RVMD) Analysts Just Slashed This Year's Revenue Estimates By 11%

May 11

We're Hopeful That Revolution Medicines (NASDAQ:RVMD) Will Use Its Cash Wisely

Mar 31

Revolution Medicines (NASDAQ:RVMD) Is In A Good Position To Deliver On Growth Plans

Dec 16

What Does The Future Hold For Revolution Medicines, Inc. (NASDAQ:RVMD)? These Analysts Have Been Cutting Their Estimates

Aug 17

Revolution Medicines (NASDAQ:RVMD) Is In A Good Position To Deliver On Growth Plans

Aug 03

Revolution Medicines EPS misses by $0.01, beats on revenue

May 10

Revolution Medicines expects no data from Amgen-sponsored clinical trial for RMC-4630

Apr 30

We're Not Very Worried About Revolution Medicines' (NASDAQ:RVMD) Cash Burn Rate

Apr 13

Stability and Growth of Payments

Fetching dividends data

Stabile Dividende: Es liegen keine ausreichenden Daten vor, um festzustellen, ob die Dividende je Aktie von RVMD in der Vergangenheit stabil geblieben ist.

Wachsende Dividende: Unzureichende Daten, um festzustellen, ob die Dividendenzahlungen von RVMD gestiegen sind.

Dividend Yield vs Market

Revolution Medicines Dividend Yield vs Market

How does RVMD dividend yield compare to the market?
Segment	Dividend Yield
Company (RVMD)	n/a
Market Bottom 25% (US)	1.5%
Market Top 25% (US)	4.7%
Industry Average (Biotechs)	2.8%
Analyst forecast in 3 Years (RVMD)	0%

Bemerkenswerte Dividende: Es ist nicht möglich, die Dividendenrendite von RVMD im Vergleich zu den unteren 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Hohe Dividende: Es ist nicht möglich, die Dividendenrendite von RVMD im Vergleich zu den besten 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Earnings Payout to Shareholders

Abdeckung der Erträge: Unzureichende Daten zur Berechnung der Ausschüttungsquote von RVMD, um festzustellen, ob die Dividendenzahlungen durch die Gewinne gedeckt sind.

Cash Payout to Shareholders

Cashflow-Deckung: Es ist nicht möglich, die Nachhaltigkeit der Dividende zu berechnen, da RVMD keine Ausschüttungen gemeldet hat.

Discover strong dividend paying companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Revolution Medicines Dividend

Dividend criteria checks 0/6

Key information

Recent dividend updates

Recent updates

Chief Operating Officer notifies of intention to sell stock

Revolution Medicines, Inc. has filed a Follow-on Equity Offering in the amount of $124.825544 million.

Consensus revenue estimates fall by 92%

Revolution Medicines, Inc. Provides Earnings Guidance for Full Year 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

New major risk - Revenue and earnings growth

Revolution Medicines, Inc. to Report Q4, 2023 Results on Feb 26, 2024

Revolution Medicines Is Hard To Understand

President of Research & Development notifies of intention to sell stock

New major risk - Shareholder dilution

Price target decreased by 7.0% to US$34.14

Consensus revenue estimates decrease by 31%

Revolution Medicines, Inc. (NasdaqGS:RVMD) completed the acquisition of EQRx, Inc. (NasdaqGM:EQRX) from a group of shareholders.

Revolution Medicines, Inc. (NasdaqGS:RVMD) completed the acquisition of EQRx, Inc. (NasdaqGM:EQRX) from a group of shareholders.

Third quarter 2023 earnings released: US$0.99 loss per share (vs US$0.87 loss in 3Q 2022)

Revolution Medicines, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Revolution Medicines, Inc. Presents Promising Clinical Activity and Safety Data from Phase 1/1b Trial of RMC-6236

New major risk - Revenue and earnings growth

Price target increased by 7.9% to US$37.14

Revolution Medicines, Inc. Provides Pipeline Updates

New minor risk - Share price stability

President of Research & Development notifies of intention to sell stock

Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-9805, an Oral, Covalent, Mutant-Selective KRASG12D(ON) Inhibitor

Revolution Medicines, Inc. Resigns Eric T. Schmidt as Board of Directors

CEO, President & Chairman notifies of intention to sell stock

Consensus revenue estimates increase by 15%, EPS downgraded

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Revolution Medicines, Inc. Reiterates Earnings Guidance for the Full Year 2023

Here's Why We're Not Too Worried About Revolution Medicines' (NASDAQ:RVMD) Cash Burn Situation

Revolution Medicines, Inc. to Report Q2, 2023 Results on Aug 08, 2023

President of Research & Development notifies of intention to sell stock

Revolution Medicines, Inc. (NasdaqGS:RVMD) entered into a definitive agreement to acquire EQRx, Inc. (NasdaqGM:EQRX) from a group of shareholders.

Price target increased by 9.4% to US$34.29

Revolution Medicines, Inc.(NasdaqGS:RVMD) dropped from Russell Small Cap Comp Value Index

Consensus revenue estimates decrease by 25%

Some Analysts Just Cut Their Revolution Medicines, Inc. (NASDAQ:RVMD) Estimates

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Revolution Medicines, Inc. Announces Executives Appointment

We Think Revolution Medicines (NASDAQ:RVMD) Can Afford To Drive Business Growth

Consensus revenue estimates fall by 34%

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Price target increased by 9.0% to US$32.22

Revolution Medicines, Inc. Announces Publication Describing Design and Synthesis of RMC-5552

We're Hopeful That Revolution Medicines (NASDAQ:RVMD) Will Use Its Cash Wisely

Revolution Medicines, Inc. to Regain Global Rights to RMC-4630 following Sanofi’s Termination of SHP2 Inhibitor Development and Commercialization Collaboration

Revolution Medicines, Inc. Updates Earnings Guidance for 2022

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Revolution Medicines, Inc. Provides Earnings Guidance for the Full Year 2022

Revolution Medicines, Inc. to Report Q3, 2022 Results on Nov 07, 2022

Chief Operating Officer notifies of intention to sell stock

Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-6291, Company’s First Mutant-Selective RAS(ON) Inhibitor

We're Not Very Worried About Revolution Medicines' (NASDAQ:RVMD) Cash Burn Rate

Revolution Medicines, Inc. Announces Executive Changes

Revolution Medicines promotes Jack Anders to CFO

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

New Forecasts: Here's What Analysts Think The Future Holds For Revolution Medicines, Inc. (NASDAQ:RVMD)

Revolution Medicines, Inc. Provides Earnings Guidance for the Year 2022

Revolution Medicines, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Revolution Medicines to raise up to $200M in stock offering

Revolution Medicines, Inc. Appoints Lorence Kim to Board of Directors

Revolution Medicines, Inc. Elects Sushil Patel to its Board of Directors

Revolution Medicines, Inc. Appoints Sushil Patel, Ph.D. as Director

Revolution Medicines, Inc. (NASDAQ:RVMD) Analysts Just Slashed This Year's Revenue Estimates By 11%

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Revolution Medicines, Inc. Reiterates Earnings Guidance for the Full Year 2022

Price target decreased to US$31.67

Revolution Medicines, Inc. to Report Q1, 2022 Results on May 09, 2022

We're Hopeful That Revolution Medicines (NASDAQ:RVMD) Will Use Its Cash Wisely

Consensus revenue estimates fall by 10%

Full year 2021 earnings: EPS exceeds analyst expectations

Revolution Medicines, Inc. to Report Q4, 2021 Results on Feb 28, 2022

Revolution Medicines, Inc. Provides Earnings Guidance for the Year Ended December 31, 2021

Revolution Medicines to Provide R&D Update, Including Expansion of Development-Stage RAS(ON) Inhibitor Pipeline, During Presentation at 40th Annual J.P. Morgan Healthcare Conference

Revolution Medicines (NASDAQ:RVMD) Is In A Good Position To Deliver On Growth Plans

Third quarter 2021 earnings released: US$0.72 loss per share (vs US$0.42 loss in 3Q 2020)